CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Clinical trial NCT03312205 · UNKNOWN

Trial details

NCT number: NCT03312205
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia Lymphoma Multiple Myeloma of Bone (Diagnosis)

Start date: 2017-08-29
Primary completion: 2019-08-29
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.